Newsletter Tool

Today’s Big News

May 28, 2025

Adios, iTeos: Biotech folds weeks after GSK TIGIT termination

GSK's $66M bet on Spero's rejected UTI antibiotic pays off with a phase 3 win

5 people charged in $600K insider trading scheme tied to Novartis' Chinook acquisition: DOJ

Merck KGaA shares phase 3 rare tumor data ahead of showdown with Daiichi and Ono

Fierce Biotech Fundraising Tracker '25: Grin grabs $140M series D; Syndeio snags $90M

Gene editing leaders call for 10-year suspension of heritable human genome editing

Featured

Adios, iTeos: Biotech folds weeks after GSK TIGIT termination

By Nick Paul Taylor

iTeos Therapeutics is throwing in the towel. Two weeks after axing its GSK-partnered TIGIT candidate, the biotech has decided to wind down operations, sell its assets and return as much of its $600 million-plus cash pile to investors as possible.

GSK's $66M bet on Spero's rejected UTI antibiotic pays off with a phase 3 win

By James Waldron

GSK’s decision to swoop in and save Spero Therapeutics’ antibiotic three years ago appears to have paid off based on a fresh phase 3 readout.

5 people charged in $600K insider trading scheme tied to Novartis' Chinook acquisition: DOJ

By Gabrielle Masson

Five people have been charged for allegedly participating in an insider trading scheme tied to Novartis’ $3.2 billion acquisition of Chinook, including a former director of the biotech’s board.

GenScript Launches GMP-like mRNA Solution to address phase-appropriate drug development needs

Merck KGaA shares phase 3 rare tumor data ahead of showdown with Daiichi and Ono

By Nick Paul Taylor

Merck KGaA has shown off data that fueled its $85 million bet on a late-phase treatment for a rare, locally aggressive tumor. The update provides a closer look at the hand Merck is holding as it gears up to fight Daiichi Sankyo and Ono Pharmaceutical for the tenosynovial giant cell tumor market.

Fierce Biotech Fundraising Tracker '25: Grin grabs $140M series D; Syndeio snags $90M

By Gabrielle Masson,Darren Incorvaia,James Waldron

The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.

Gene editing leaders call for 10-year suspension of heritable human genome editing

By Darren Incorvaia

An international group of gene editing leaders has put out a call for a 10-year ban on heritable human genome editing (HHGE), extending a moratorium that was first proposed in the fallout of a Chinese researcher’s widely decried use of CRISPR on human embryos.

InflaRx drops rare skin disease study for COVID med vilobelimab after futility signal

By Fraiser Kansteiner

An independent data monitoring committee assessing a phase 3 trial for InflaRx's vilobelimab in pyoderma gangrenosum has urged the German drugmaker to stop the study early for futility. Given the trial’s outcome, InflaRx said it plans to stop development of vilobelimab in the rare inflammatory skin disorder.

AbbVie's Allergan Aesthetics unit plots 202 layoffs after recent sales slide

By Zoey Becker

The layoffs at Allergan's Irvine, California, headquarters are effective on July 22, according to a recent filing with the state.

CDC pulls COVID vaccine recommendation for pregnant women, healthy children: RFK Jr.

By Zoey Becker

The CDC's recommended immunization schedule no longer includes COVID vaccines for healthy children and pregnant women, HHS secretary Robert F. Kennedy Jr. announced on Tuesday.

Fierce podcasts

Don’t miss an episode

A Fierce breakdown of the 'most favored nation' executive order

This week on "The Top Line," Fierce Pharma breaks down President Donald Trump’s executive order targeting drug prices and what it could mean for the industry as broader policy shifts unfold.

How Grow Therapy hopes to prevent patient dropout during referrals

Angela Hwang on her pivot from Big Pharma to biotech

Resources

Whitepaper

Upcoming Fierce Events

8-11

Sep

Fierce Pharma Week

Philadelphia, PA

Sep

Fierce Pharma Marketing Awards

Philadelphia, PA

7-9

Oct

Fierce Biotech Week

Boston, MA

12-13

Nov

Diversity, Equity & Inclusion Forum

Free Virtual Event

Nov

Fierce 50 Awards Gala

The Lighthouse at Pier 61 in New York City

View all events

This email was sent to [email protected] as part of the Fierce Biotech email list.